Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Biotechnology

AstraZeneca Buys Omniose to Add Bacterial Vaccine Technology

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
AstraZeneca Buys Omniose to Add Bacterial Vaccine Technology

AstraZeneca has acquired Omniose, a preclinical vaccine company in St. Louis, Missouri, Omniose announced on 10 November 2026. Omniose becomes a wholly owned subsidiary inside AstraZeneca's Infectious Disease Unit, bringing a platform that makes conjugate vaccines against bacterial infections in a single engineered E. coli cell. Financial terms were not disclosed.

The purchase ends a partnership that started in January 2024, when AstraZeneca took exclusive rights to the Omniose technology for up to three years. The target is bacteria that cause serious infections, including strains that resist antibiotics.

Key Highlights:
  • Deal: AstraZeneca acquires Omniose outright; announced 10 November 2026 via Business Wire.
  • Price: not disclosed.
  • Structure: Omniose becomes a wholly owned subsidiary in AstraZeneca's Infectious Disease Unit.
  • Technology: one engineered E. coli cell produces the sugar antigen, the carrier protein and the enzyme that joins them.
  • Company: founded in 2016, nearly 25 staff, mostly scientists; about $14.5 million raised, mainly from NIH grants (St. Louis Magazine).
  • Stage: all programmes are preclinical. No human data have been published.

What does Omniose bring to AstraZeneca?

Conjugate vaccines attach a bacterial surface sugar (a polysaccharide) to a carrier protein, which helps the immune system respond strongly to the sugar. Most are made by chemical conjugation, a multi-step process. Omniose engineers E. coli to produce the polysaccharide, an engineered carrier protein and a conjugating enzyme inside one cell, so the joining happens biologically.

In its 2024 collaboration release, Omniose said the enzyme-based method streamlines manufacturing compared with chemical conjugation. BioPharm International notes that the acquisition announcement gave no yield, purity or cost data to show that advantage.

Benjamin Moutier, Senior Vice President, Infectious Disease at AstraZeneca, said the platform "represents a differentiated approach to engineering conjugate vaccines", according to the release as reported by BioPharm International.

How did the deal come about?

On 5 January 2024, Omniose announced an exclusive collaboration giving AstraZeneca rights to its bioconjugation platform for up to three years. The work was to research vaccines for bacterial pathogens in AstraZeneca's early Vaccines and Immune Therapies pipeline, including multidrug-resistant bacteria. That exclusivity would have run to January 2027 at the latest. Mark Esser, then Vice President, Early R&D Vaccines and Immune Therapies at AstraZeneca, said in that release that "the development of alternative preventative interventions is critical".

Omniose and AstraZeneca: timeline from company releases and reports
DateEvent
2016Omniose founded by Mario Feldman, Christian Harding and Christine Szymanski
2017Arch Grants award, St. Louis
April 2022Timothy Cooke appointed chief executive
October 2022NIH grant of $3.6 million for a Klebsiella pneumoniae vaccine
September 2023NIH grant of up to $3.0 million for a Group B Streptococcus vaccine
5 January 2024Exclusive research collaboration with AstraZeneca
10 November 2026Acquisition by AstraZeneca announced

Who is Omniose?

St. Louis Magazine reports that Omniose works from BioGenerator's laboratories in the Cortex Innovation District in St. Louis and has nearly 25 employees, most of them scientists. It raised about $14.5 million, mostly non-dilutive NIH grants, and had no venture capital funding. BioGenerator holds equity. The pipeline covers Klebsiella, Pseudomonas and Group B Streptococcus, plus two undisclosed programmes with AstraZeneca.

Timothy Cooke, who led Omniose as chief executive, told the magazine: "The acquisition by AstraZeneca is a great outcome for both organizations." Jim McCarter of BioGenerator said he hoped AstraZeneca would keep a St. Louis footprint, which the company has not confirmed.

What is known and not known about the deal
ItemStatus
Purchase priceNot disclosed
Milestone or earn-out paymentsNot disclosed
Target pathogens of the AstraZeneca programmesNot disclosed
Clinical trial timelinesNot disclosed
Future of the St. Louis site and staffNot confirmed

Why does AstraZeneca want bacterial vaccines?

Both the 2024 collaboration and the 2026 acquisition announcement name serious bacterial infections, including those complicated by antimicrobial resistance, as the target. Cooke told St. Louis Magazine that the pathogens Omniose works on kill a combined 2.7 million people a year; that is his estimate and the magazine gave no separate source. Omniose's NIH grants funded work on vaccines against Klebsiella pneumoniae and Group B Streptococcus.

Is there an Irish angle?

The deal itself has no announced Irish element: Omniose is a US company and its programmes are preclinical. AstraZeneca is a major employer in Ireland through Alexion, AstraZeneca Rare Disease. Alexion says it employs over 1,300 people across two manufacturing facilities in Dublin and Athlone, runs its global supply chain from Ireland and hosts several global teams here. Priya Life Science tracks the group on its AstraZeneca and Alexion, AstraZeneca Rare Disease company pages, and AstraZeneca-sponsored studies on the AstraZeneca trials page.

Frequently asked questions

How much did AstraZeneca pay for Omniose?

The price was not disclosed by either company.

What is bioconjugation?

It is a way of making conjugate vaccines in which a living cell, here engineered E. coli, builds the sugar antigen and carrier protein and joins them with an enzyme, instead of joining them chemically.

Are any Omniose vaccines in human trials?

No. The programmes are preclinical and no clinical safety or immune response data have been published.

Will Omniose keep operating in St. Louis?

That has not been confirmed. Omniose now operates as a subsidiary within AstraZeneca's Infectious Disease Unit.

Outlook

The next milestone to watch is a first clinical trial of a vaccine built on the Omniose platform, and whether AstraZeneca names its target pathogens. Priya Life Science will update this report if AstraZeneca publishes further detail.

Sources

Cover image: the AstraZeneca Discovery Centre on the Cambridge Biomedical Campus, UK. It is not an Omniose site. Photo: Mr Ignavy, geograph.org.uk, CC BY-SA 2.0, via Wikimedia Commons and geograph.org.uk, cropped.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Biotechnology

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment